SSD AF Rx
Generic Name and Formulations:
Silver sulfadiazine 1%; crm; alcohol-free.
Par Pharmaceutical, Inc.
Indications for SSD AF:
Prophylaxis and treatment of sepsis in 2nd and 3rd degree burns.
Apply 1–2 times daily aseptically to approximately 1/16 inch depth to cleansed and debrided burns. Reapply promptly if removed. Continue until wound is healed. May be occluded.
Premature infants. Within first 2 months of birth. Late pregnancy.
G6PD deficiency. Impaired renal or hepatic function. Monitor serum sulfa levels and renal function in extensive burns. Pregnancy (Cat.B). Nursing mothers: not recommended.
Leukopenia increased with concomitant cimetidine. May inactivate debriding enzymes.
Transient leukopenia, skin necrosis, erythema multiforme, skin discoloration, burning sensation, rash, fungal overgrowth, interstitial nephritis, systemic sulfonamide reactions.
SSD—25g, 50g, 85g, 400g
SSD AF—50g, 400g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma